Protagonist Therapeutics, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based therapies for hematology, inflammatory, and immunomodulatory diseases. The company operates as one segment and has no approved products or product-sales revenue. This unaudited Form 10-Q covers the three months ended March 31, 2022, filed May 5, 2022.
- Key programs included rusfertide (PTG-300) for polycythemia vera and other blood disorders, PN-943 for ulcerative colitis, and PN-235 under the Janssen collaboration.
- Enrollment was completed in the Phase 2 REVIVE trial for rusfertide and the Phase 2 IDEAL trial for PN-943. The company initiated screening for the global Phase 3 VERIFY trial of rusfertide.
- Janssen discontinued development of PTG-200 and PN-232 in favor of PN-235, and initiated the FRONTIER 1 Phase 2b trial in psoriasis.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| License and collaboration revenue | $25.7 million | $6.2 million | +$19.5 million, or 316% |
| Research and development expense | $36.3 million | $24.2 million | +$12.1 million, or 50% |
| General and administrative expense | $10.5 million | $6.0 million | +$4.6 million, or 76% |
| Loss from operations | $(21.1) million | $(24.0) million | Improved by $2.9 million |
| Net loss | $(20.9) million | $(24.0) million | Improved by $3.1 million, or 13% |
| Net loss per share | $(0.43) | $(0.54) | Improved |
| Cash used in operating activities | $(37.7) million | $(28.8) million | Use increased by $8.9 million |
- Operating margin was approximately negative 82%; net loss margin was approximately negative 81%.
- Cash, cash equivalents, and marketable securities totaled $305.3 million at March 31, 2022, compared with $326.9 million at December 31, 2021. Cash and cash equivalents were $98.5 million, and current marketable securities were $206.8 million.
- Accumulated deficit was $430.3 million. Total liabilities were $46.5 million, consisting primarily of operating lease liabilities and operating payables; the filing does not identify outstanding debt financing.
- Cash flow was affected by a $23.6 million increase in receivables from Janssen, primarily related to the $25.0 million milestone recognized as receivable during the quarter.
- Financing activities provided $16.9 million, including $14.6 million of net proceeds from the January 2022 at-the-market offering and $2.6 million from employee equity issuances and option exercises.
- Stock-based compensation was $5.9 million, compared with $2.7 million in the prior-year quarter.
Material changes versus the prior comparable period
- Revenue increased primarily because the company became eligible for a $25.0 million Janssen milestone upon dosing of the third patient in the FRONTIER 1 trial. The milestone was received in April 2022.
- Research and development spending increased mainly from higher PN-943 costs, including IDEAL manufacturing and clinical expenses, and higher rusfertide costs associated with VERIFY. These increases were partly offset by lower PN-235 costs after completion of its Phase 1 trial.
- General and administrative expenses rose due to higher personnel costs, stock-based compensation, and costs supporting business growth.
- The company sold 422,367 shares under its ATM facility for $14.6 million of net proceeds, increasing shares outstanding to 48.6 million at March 31, 2022.
- Cash used in operations increased despite the lower net loss, primarily because of the milestone-related collaboration receivable and ongoing clinical investment.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects continued operating losses and states that additional financing will be required to advance programs toward regulatory approval and potential commercialization.
- Based on its current operating plan, the company believes existing cash, cash equivalents, and marketable securities will fund anticipated requirements for at least 12 months from the filing date, but this estimate depends on assumptions that may prove incorrect.
- PN-943 IDEAL topline data reported in April 2022 showed that the 450 mg twice-daily arm did not meet the primary endpoint, while the 150 mg twice-daily arm achieved 27.5% clinical remission and a 13% placebo-adjusted difference. The company described the study as achieving clinical proof of concept and is evaluating a Phase 3 design, subject to regulatory guidance and potential partnering or financing.
- In April 2022, the FDA indicated its intent to rescind rusfertide’s Breakthrough Therapy Designation. Fast Track designation remained active, and the company requested a meeting with the FDA.
- Rusfertide trials had previously been placed on clinical hold after tumor findings in a mouse carcinogenicity study; the FDA lifted the hold in October 2021 following the company’s response and implementation of additional safety measures.
- COVID-19-related enrollment, site, manufacturing, supply-chain, and operational disruptions remain risks. The company also closed clinical sites in Ukraine and Russia in March 2022 because of the military conflict.
- Under the Zealand settlement, the company owes a $1.5 million payment in August 2022 and may owe up to $2.75 million in additional future rusfertide development milestones. No related legal accrual was recorded at March 31, 2022.
- The company remains eligible for substantial future Janssen development, regulatory, and sales milestones, but achievement is uncertain and future milestones are generally constrained from revenue recognition until development or regulatory uncertainty is resolved.
Most important facts for investors to verify
- Progress, enrollment, safety, and regulatory status of rusfertide’s VERIFY Phase 3 program, including the FDA’s proposed rescission of Breakthrough Therapy Designation.
- Whether PN-943’s 150 mg twice-daily efficacy signal is replicated and supports advancement into Phase 3, and the terms of any potential partner or financing arrangement.
- Janssen’s continued development of PN-235, timing of additional trials, and the probability and timing of future milestone payments.
- Operating cash burn, clinical-trial cost escalation, and the timing and terms of anticipated additional financing.
- Potential effects of COVID-19, geopolitical disruptions, manufacturing constraints, patient recruitment, and third-party clinical research organizations on development timelines.
- The filing text contains an apparent inconsistency in one cash-flow discussion, which refers to the $25.0 million milestone as relating to a PN-943 trial, while the collaboration disclosures identify the milestone as relating to Janssen’s PN-235 FRONTIER 1 trial; investors should verify the underlying filing and subsequent disclosures.